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The dissemination of a clone of community genotype methicillin-resistant Staphylococcus aureus (CG-MRSA) that is related to
USA300 has been reported in Latin America. We recently detected isolates of a new clone of CG-MRSA (spa type t1635 and
ACME-negative) that was genetically unrelated to the USA300 clone and that causes infections in children in Colombia. This
finding indicates the appearance of a new clone of CG-MRSA in our region.
USA300 is the predominant clone of community genotypemethicillin-resistant Staphylococcus aureus (CG-MRSA) in
North America, and it has been reported in many other regions of
the world, including in Latin America (1, 2). This clone usually
(ST8-MRSA-IVa) harbors the sek, seq, bsaB, lukF-PV, and lukS-PV
genes, which encode the staphylococcal enterotoxins K and Q,
bacteriocin, and Panton-Valentine leukocidin (PVL), respec-
tively. Additionally, the clone typically contains a type I agr
operon, a type t008 spa gene, and the arginine catabolic mobile
element (ACME). Since 2006, the spread of a CG-MRSA clone
that is genetically related to the USA300 clone and that causes
infections in adults and children has been reported in Colombia
and several South American countries (2–4). This variant (ST8-
MRSA-IVc) is PVL positive, harbors the sek, seq, and bsaB genes,
and, unlike USA300, does not possess ACME. Recently, in a pro-
spective multicenter study of MRSA infections in pediatric pa-
tients in Bogotá, Colombia, we detected isolates of a new clone of
CG-MRSA that was genetically unrelated to USA300. The purpose
of this study was to determine the genetic and molecular charac-
teristics of the isolates belonging to this emerging clone.
All CG-MRSA (154 isolates with SCCmec type IV and/or lukF-
PV, lukS-PV, seq, sek, or bsaB) isolated from patients with con-
firmed clinical infections were collected systematically from 15
hospitals between April 2009 to June 2011 in Bogotá, Colombia.
Informed consent and approval by the institutional review boards
of the participating hospitals were obtained. Molecular character-
ization of the isolates included PCR amplification of the genes nuc,
mecA, lukF-PV, lukS-PV, sausa300_0808 (hypothetical protein of
pathogenicity island 5), sausa300_0400 (exotoxin of the genomic
island Sa), sak, bsaB, etb, eta, hlg, sea, seb, sec, seg, seh, sei, sej, sek,
sel, sem, sen, seo, sep, seq, arcC, and opp (the last two were used as
ACME markers) as well as SCCmec, spa, and agr typing (5, 6). The
genetic relatedness between the isolates was established by multi-
locus sequence typing (MLST) and restriction of the arcC and gmk
genes (7), and pulsed-field gel electrophoresis (PFGE) results were
interpreted according to the criteria of Tenover and colleagues
(8). The profile of susceptibility to 11 antibiotics was determined
by the agar dilution method recommended by the Clinical and
Laboratory Standards Institute (17).
Among 154 CG-MRSA isolates analyzed, 139 (90.3%) were
genetically related to the USA300 clone, although they exhibited
SCCmec IVc (3.1.2) and had no ACME, similar to clones previ-
ously reported in Colombia and in the Andean region (2, 3). How-
ever, 15 (9.7%) isolates exhibited PFGE pulsotypes unrelated to
that of USA300 (6 different bands and similarities of less than
80%). Of these, 8 (5.2%) isolates had closely related PFGE pulso-
types and type t1635 spa (YHGFMBO) (Fig. 1). Molecular char-
acterization of these 8 isolates demonstrated that they contained
SCCmec IVa and the genes lukF-PV, lukS-PV, seq, sek, bsaB, sak
(prophage 3 specific), and group I agr. All isolates belong to clonal
complex 8 (CC8). Representative isolates of the pulsotypes were
analyzed by MLST, which identified two isolates as ST8 and two
others as ST923. As in USA300, the seq and sek genes were found
within pathogenicity island 5 (SaPI5), but unlike this clone, they
did not contain ACME and had a 54-bp insertion in the
sausa300_0808 gene found in SaPI5. This insertion has been iden-
tified only in pathogenicity islands SaPIov2 and vSa3 of strains
ED133 (isolated from a sheep) and MW2, respectively. These re-
sults reveal the emergence of a CG-MRSA clone (CC8-MRSA-
IVa; PVL positive and ACME negative) that, although it has some
molecular features similar to USA300, is not genetically related to
this clone. Susceptibility assays demonstrated that 8, 5, and 1 iso-
lates were resistant to tetracycline (confirmed by the presence of
the tetK gene), erythromycin, and gentamicin, respectively. One
isolate exhibited multiple resistances to erythromycin, gentami-
cin, and tetracycline (Fig. 1). All of the isolates that were resistant
to erythromycin exhibited an M phenotype.
The 8 isolates of the new clone were recovered from 6 pediatric
patients (of various ages) and 2 newborns who had been treated at
6 of the 15 participating institutions, suggesting that these isolates
were not associated with an epidemic event at one institution
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(Table 1 and Fig. 1). Six (75%) infections were classified as com-
munity onset MRSA (CO-MRSA; infection identified within the
first 48 h of hospital admission) in children without health care-
associated risk factors, whereas the remaining 2 (25%) cases were
classified as hospital-onset MRSA infections (HO-MRSA, infec-
tion identified after 48 h of hospital admission) detected in two
neonates who were treated at a single institution in June and July
2010, suggesting a common source and possible cross-transmis-
sion. No infections were detected in 2009, whereas in 2010 and
2011, 3 and 5 cases, respectively, were detected. These findings
suggest an increased frequency of infections during the previous
year, although the study was conducted only until June 2011. The
clinical diagnosis of the patients included 5 skin and soft tissue
infections (SSTI; 3 skin abscesses and 2 cases of abscessed celluli-
tis), 2 surgical-site infections (SSI) in the two newborns (one with
deep SSI and another with organ space SSI that produced endocardi-
tis), and 1 case of septic arthritis. Six patients were treated definitively
with active antimicrobials for MRSA infections, and one was treated
with cephalexin. Three patients (37.5%) required a PICU (pediatric
intensive care unit) stay because of the severity of their infections; two
had deep and organ space SSI, respectively, and the other was in a
septic phase of septic arthritis. Five patients (62.5%) underwent inci-
sion and drainage, and full recovery was observed in all 8 cases.
Recently, the identification of isolates of S. aureuswith spa type
t1635 has been reported; some of these isolates exhibit molecular
characteristics similar to those found in this study (9, 10). Accord-
ing to the reports on the Ridom Spa Server (http://spaserver
.ridom.de/), the spa type t1635 has been found in European coun-
FIG 1 Dendrogram of the 8 isolates belonging to the new CG-MRSA clone collected from pediatric infections. The GelCompar II program (Applied Maths NV)
was used with a tolerance position of 1.5% and a Dice coefficient of 1.0%. USA300-0114-FPR3757 and CHL93 were used as standards. PFGE patterns were
considered different when they had a similarity lower than 80%. The sea, seb, sec, sed, see, seg, seh, sel, sem, sen, seo, etb, hlg, and tst genes were not found in the
isolates. NR, spa type number not reported (for the Chilean clone, the repeats are TIMEMDMGMGMK); MLSb, macrolide-lincosamide-streptogramin B
resistance phenotype (M is resistance only to macrolides and C is resistance to macrolides and lincosamides); HI, hospital institution.
TABLE 1 Characteristics of pediatric patients infected with the emergent CC8-MRSA-IVa PVL ACME clone
Characteristic Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8
Date collected Jun 2010 Jul 2010 Oct 2010 Jan 2011 Jan 2011 Feb 2011 Feb 2011 Mar 2011
Case definitiona HO-MRSA HO-MRSA CO-MRSA CO-MRSA CO-MRSA CO-MRSA CO-MRSA CO-MRSA
Sex Male Male Female Male Female Male Male Female
Age (years) 0.003 0.003 10.7 14.7 5.1 1.2 15.6 0.05
Origin Urban Urban Urban Urban Urban Rural Urban Urban
Admission siteb NICU NICU ER ER ER ER HA ER
Prior respiratory
diseasesc
None None None None None Asthma-COPD None None
Prior infectious diseases None None None None Abscess Abscess None None
Clinical diagnosisd SSI SSI SSTI SSTI SSTI SSTI SSTI Osteoarticular
septic arthritis
Prior use of clinical
devices
Yes Yes No No No No No Yes





OXA-AMK OXA-GEN CEF OXA-LEX OXA OXA
Definitive antimicrobial
therapyf
VAN VAN-SXT SXT CLI CLI-AMK-ERY LEX VAN-RIF-SXT
Clinical outcome Improvement Improvement Improvement Improvement Improvement Improvement Improvement Improvement
Duration of hospital
stay (days)
58 17 6 6 9 4 6 27
a HO-MRSA, hospital-onset MRSA infections (specimen isolated48 h after hospital admission); CO-MRSA, community-onset MRSA infections (specimen isolated48 h after
hospital admission).
b NICU, neonatal intensive care unit; ER, emergency room; HA, hospital admission.
c COPD, chronic obstructive pulmonary disease.
d SSI, surgical-site infection organ space; SSTI, skin and soft tissue infection.
e PICU, pediatric intensive care unit; HD, hospitalization and drainage.
f SXT, trimethoprim-sulfamethoxazole; TZP; piperacillin-tazobactam; AMP, ampicillin; AMK, amikacin; CLI, clindamycin; CEF, cephalothin; ERY, erythromycin; LEX, cephalexin;
RIF, rifampin; OXA, oxacillin; GEN, gentamicin; VAN, vancomycin.
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tries, such as Austria, France, Germany, Norway, Spain, Sweden,
and Switzerland, but with a low circulation frequency. While an-
alyzing infections caused by PVL S. aureus in Spain, Blanco and
colleagues found two isolates with spa type t1635: one methicillin-
susceptible S. aureus (MSSA) strain and one MRSA strain, the
latter having molecular characteristics similar to those of the new
clone detected (ST8-MRSA-IVa; PVL positive and ACME nega-
tive) and being genetically unrelated to USA300 (11). In Latin
American countries, such as Colombia and Venezuela, some re-
lated isolates have been found; however, they were not identified
as having a spa type, an agr group, or the insertion in the
sausa300_0808 gene found in SaPI5, and those isolates show some
differences in PFGE pulsotype (2, 12).
The possible emergence of this new clone of CG-MRSA that is
causing infections in children of all ages in Bogotá could lead to
temporal clonal replacement in the near future, as has happened
before in Colombia and elsewhere, when new clones have
emerged to replace existing ones. In the 1990s, the majority of
MRSA infections in Colombia were hospital acquired and caused
by the pediatric clone (ST5-MRSA-IV; PVL and ACME negative)
(13). Subsequently, Cruz and colleagues reported the spread of a
new dominant clone, the Chilean clone (ST5-MRSA-I; PVL and
ACME negative), which has replaced the pediatric clone and cir-
culates in Argentina, Chile, and Paraguay (14). The circulation of
CG-MRSA isolates (ST8-MRSA-IVc) in Colombia was first re-
ported in 2006 (4); subsequently, the frequency of these infections
was approximately 25% of all MRSA infections in adults in 2008
(2, 15). Our group has recently determined that more than 95% of
infections with MRSA in the pediatric population were caused by
CG-MRSA isolates (16). These findings demonstrate the genetic
success of the CG-MRSA clones in recent years, displacing the
traditional hospital genotype MRSA clones (HG-MRSA; isolates
with genetic characteristics traditionally found in strains isolated
in hospital environments), as has begun to be reported in other
countries (9). Possibly, this new emerging clone (CC8-MRSA-
IVa; PVL positive and ACME negative) and USA300 both origi-
nated from related MSSA isolates which acquired mobile genetic
elements or single-nucleotide polymorphisms that thereafter dif-
ferentiated the clones, because although the two clones exhibit low
relatedness according to PFGE, they belong to the same clonal
complex (CC8). Despite the small number of the novel isolates,
given their similarities to USA300, the multiple-antibiotic-resis-
tant phenotype raises the concern that they may have a significant
clinical impact in the event that they are easily transmissible. Fur-
thermore, the emergence of new CG-MRSA clones could also be
caused by the acquisition of SCCmec by various clones of S. aureus
in the community, causing the clones that experience the least
genetic cost in the acquisition of this element to predominate. It
has been frequently observed that although many clones have the
ability to acquire the same SCCmec, only a few predominate in
their respective geographic niches (9), suggesting that there are
specific genetic determinants for different regions.
The results of this study demonstrate the emergence of a new
clone of MRSA with a community genotype and genetic charac-
teristics that are different from those of USA300. This new clone,
although still present at a low frequency (5.4%), may increase in
circulation and disseminate. Therefore, it is necessary to continue
surveillance studies, supported by molecular biology techniques,
both in hospitals and in the community in order to monitor the
behavior of infections caused by this distinct and newly emerging
clone.
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